explore -WSS

explore

author：comprehensive 2025-10-01 15:29:49 - browse：588

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Cytokinetics CEO stresses company can launch heart drug on its own

explore

WSS

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Second House panel advances two

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Bird flu: Don't repeat Covid's 'health versus the economy' framing

How to use technology to prevent future drug shortages

Data integrity in scientific journals requires "effort" by publishers, institutions

leisure time

explore

Gilead needs Arcellx more than ever

focus

Jerome Adams on the need for new antivirals for Covid

Anavex keeps shifting the goalposts in its clinical trials

Medical leaders decry Supreme Court decision on affirmative action

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA panel issues narrow recommendation for Covid vaccine booster doses

Alkermes shareholders re

Emergent cuts jobs, executive role in business shake

Malaria cases in Florida and Texas: Here’s what you need to know

Naloxone nonprofit donates 200,000 doses after FDA approval

hotspot

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

How to use technology to prevent future drug shortages

NVIDIA and Google execs on the future of AI and drug discovery

Naloxone nonprofit donates 200,000 doses after FDA approval

The best solution to the drug shortages problem

It's time to retire 'poor historian' from clinicians' vocabularies

explore

focus

hotspot

explore